UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage

Formycon-Bioeq Partnered Ongavia Receives First European Approval In UK

Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.

UK red on map of Europe
The UK has given Teva and partner Formycon a first European ranibizumab approval • Source: Shutterstock

Teva could now be in line for the world’s first launch of a biosimilar rival to Lucentis (ranibizumab), after the UK’s Medicines & Healthcare Regulatory Agency approved the Ongavia version that was developed by Bioeq and Formycon under the FYB201 designation.

Under an exclusive commercialization deal struck last year, Teva has rights to FYB201 in Europe, as well as Canada, Israel,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.